 鲜花( 85)  鸡蛋( 2)
|

楼主 |
发表于 2015-2-28 21:48
|
显示全部楼层
Stock soars after Cold-fX wins crucial approval
; J2 p; x, L* L$ \1 Q9 u) l+ L
2 S& p3 A, b# X) O, V' g& b8 q; `9 yEDMONTON - CV Technologies Inc. shares rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX.! C; m. m& [% p
, ?6 e% D0 t9 U% ~# ZBY THE EDMONTON JOURNAL FEBRUARY 16, 2007$ T7 D+ i2 p) _7 `" G5 F8 h O
9 Z, E; i- l" J! p7 m
1 ?* Z# {0 v% iEDMONTON - CV Technologies Inc. SHARES rose nearly 60 per cent Thursday after Health Canada approved the claims at the core of the company's marketing of its cold and flu drug Cold-fX." n: I i9 V5 K( Q) ^* n% O
& |2 o0 |1 ]* N; JThe agency said CV Technologies can continue to market Cold-fX as helping "to reduce the frequency, severity and duration of cold and flu symptoms by boosting the IMMUNE SYSTEM."
- y7 s! ]- x& H, S, E. V4 J% K K. e: b: o
The APPROVAL follows a review of seven clinical trials and more than 10 years of research about the product.6 h8 C* ^8 O; z; h* o
# q" ~9 p8 i4 |; y, d' m) o
It should create even more confidence among consumers and medical professionals that the product works, CEO Jacqueline Shan said Thursday.
6 N% \) d5 ^7 V( X4 L* }& |$ o* q
It certainly instilled confidence in the market, as shares closed at $2.90 on THE TORONTO STOCK EXCHANGE, up $1.08 on a volume of 4.6 million.
: x8 \& u1 `& b) R: S' D/ m+ t1 b/ m; C. S3 y) T
"As a scientist, it's one of the highlights of my CAREER," Shan said.
2 X! c" i1 C% O' e& l' @, A( ]
' Z7 r) ?1 j) J) k7 R7 B"This approval is a breakthrough in realizing our vision of being a global leader in developing products for disease prevention."+ ~" H- E* M1 q/ V
1 a0 J& G6 n W+ H- a- Z9 K
It's Cold-fX's strongest medical recognition to date, said Shan. It means the company can advertise the HEALTH BENEFITS more effectively to consumers and health professionals, she said.
6 _ E$ I5 X$ d& w5 {) M! b/ {: k
" ^9 V; _/ o# F# q2 A. n" L/ NGinseng-based Cold-fX is already the top-selling cold and flu treatment in Canada, but Shan said there is plenty of room for more growth.+ t3 o. E$ v m8 _4 O. D% t
# L- |. C4 b2 S$ f. ]: y$ NThe approval will also help raise the product's PROFILE in the lucrative U.S. market, which Cold-fX entered in October. The move came with a new marketing push, using former Oilers superstar Mark Messier as its spokesman.7 D% @8 v# s) a) }4 |
4 A! v$ k5 {& m3 }- _! j0 B$ g: {. U+ j8 K; m' ]# Z1 p; _7 Q1 y
http://www.canada.com/story.html ... 9-be80-f40f1426f662 |
|